The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.
The Phase III TEMPO-1 trial enrolled 529 adults, between the ages of 40 and 80, diagnosed with Parkinson’s for less than three years.
Longboard Pharmaceuticals has commenced the Phase III DEEp SEA Study of bexicaserin for treating seizures in Dravet syndrome ...